Format

Send to

Choose Destination
Eur J Clin Nutr. 2005 Mar;59(3):384-92.

Effects of single and long-term administration of wheat albumin on blood glucose control: randomized controlled clinical trials.

Author information

1
Nisshin Pharma Inc., Tokyo, Japan.

Abstract

OBJECTIVE:

To examine the effects of single and long-term administration of wheat albumin (WA) on blood glucose levels and blood glucose control, respectively.

DESIGN:

Randomly arranged crossover trial for single administration in healthy subjects and double-blinded randomized controlled trial for long-term administration (3 months) in diabetic patients. In vitro alpha-amylase inhibitory activity of WA was also determined.

SETTING:

Central Research Laboratories of Nisshin Flour Milling Co. Ltd. (Saitama, Japan) for single administration and Aiwa Clinic (Saitama, Japan) for long-term administration.

SUBJECTS:

A total of 12 healthy adult male volunteers for the single administration and 24 type II outpatient diabetics with mild hyperglycemia for the long-term administration.

INTERVENTIONS:

Subjects took soups containing 0, 0.25, 0.5, and 1.0 g WA before test meals for single administration, and patients took soups with or without 0.5 g WA before every meal for the long-term (3 months) administration.

RESULTS:

In vitro alpha-amylase inhibitory activity of WA was 150 times that of wheat flour. In the single administration experiment, WA suppressed peak postprandial blood glucose levels in a dose-dependent manner: 31, 47, and 50% reduction after 0.25, 0.5, and 1.0 g administrations, respectively. In the long-term administration, 0.5 g of WA did not affect fasting blood glucose levels, whereas it reduced hemoglobin A1c levels. No significant adverse effects such as hypoglycemia or gastrointestinal disturbances were observed in the two experiments.

CONCLUSION:

In the treatment of type II diabetic patients, WA might be a useful functional food, which, with diet and exercise, could help to improve blood glucose control without any critical adverse effects.

PMID:
15674303
DOI:
10.1038/sj.ejcn.1602085
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center